Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin;Immuntoleranzinduktion mit hoch dosiertem FVIII und intravenösen Immunglobulin-Pulsen

Hamostaseologie

Volumn 30, Issue SUPPL.1, 2010, Pages 119-121

  Stiefel, M ^a   Pinkwart, C ^a   Merkel, R Haase N ^a   Forsberg, D ^a   Mauz Korholz C ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

FVIII inhibitors; Haemophilia A; Ivig

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN;

ARTICLE; BLOOD; CASE REPORT; CHILD; DRUG ANTAGONISM; GENETICS; HALF LIFE TIME; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTRON; MALE;

CHILD; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INTRONS; ISOANTIBODIES; MALE;

EID: 79952111720     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Oldenburg J, Schroder J, Graw J et al. Significance of mutation analysis in patients with haemophilia A. Hamostaseologie 2003; 23:6-12.
2. Astermark J, Berntorp E. Malmo International Brother Study (MIBS): an international survey of brother pairs with haemophilia. Vox Sang 1999; 77 (Suppl 1):80-82.
3. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
4. Oldenburg J, Picard JK, Schwaab R et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-242.
5. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-3745.
6. Astermark J, Oldenburg J, Pavlova A et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-3172.
7. Astermark J, Wang X, Oldenburg J et al. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-265.
8. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-603.
9. Van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-479.
10. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-155.
11. Van den Berg HM, Roosendaal G, Voorberg J, Mauser-Bunschoten EP. Inhibitor development in a multitransfused patient with severe haemophilia A. Thromb Haemost 1999; 82: 151-152.
12. Scandella D. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII. Semin Thromb Hemost 2002; 28: 291-296.
13. Ananyeva NM, Lacroix-Desmazes S, Hauser CA et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004; 15: 109-124.
14. Lacroix-Desmazes S, Wootla B, Dasgupta S et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol 2006; 177: 1355-1363.
15. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'bonn protocol'. Vox Sang 1996; 70 (Suppl 1): 30-35.
16. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995 Aug 1;86:983-8.
17. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmo protocol update. Haematologica 2000; 85: 48-50.
18. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136: 12-25.
19. Wadhwa M, Dilger P, Tubbs J et al. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84: 2021-2030.
20. Ghio M, Contini P, Ottonello L et al. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 2003; 89: 365-373.
21. Hausl C, Ahmad RU, Sasgary M et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005 Nov 15;106:3415-22.
22. Gilles JG, Desqueper B, Lenk H et al. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-1388.
23. Mauz-Korholz C, Korholz D, Gobel U. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Thromb Haemost 1997; 78: 959.
24. Kubisz P, Plamenova I, Holly P, Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med Sci Monit 2009; 15: CS105-111.
25. Behrmann M, Pasi J, Saint-Remy JM et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-219.
26. Scandella D, DeGraaf Mahoney S, Mattingly M et al. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci U S A 1988; 85: 6152-6156.
27. Orsini F, Rotschild C, Beurrier P et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-1290.
28. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
29. Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
30. Kurth MA, Dimichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-55.